Table 1.
Summary of all examined variables.
| ID | Diagnosis | Specimen | Tumor Size (mm) | pTNM Stage at Surgery | Death | Survival/Follow-Up Time (Months) | Adjuvant Therapy | % of Tumor Cells | PD-L1 Positivity of Tumor Cells | Pathogenic/ Likely Pathogenic |
Uncertain Significance |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | UCOGC+PDAC | Resection | 30 mm | T2N1 | Yes | 5.7 | Chemotherapy | 70% | 10% | KRAS, TP53 | APC |
| 2 | UCOGC | Resection | 70 mm | T3N1 | Yes | 1.2 | No | 50% | 75% | CIC | |
| 3 | UCOGC | Resection | 90 mm | T3N0 | Yes | 8.6 | Unknown | 60% | 5% | KRAS, TP53 | |
| 4 | UCOGC | Resection | 18 mm | T1cN0 | No | 56.4 | Chemotherapy | 60% | 30% |
TP53, KRAS, CDKN2A, SMAD4 |
|
| 5 | UCOGC | Resection | 60 mm | T3N1 | No | 58.3 | Chemotherapy | 70% | 90% | TP53, KRAS, GNAS, CDKN2A | RET |
| 6 | UCOGC | Lymph node metastasis | unknown | TXN1 | Yes | 4.4 | Unknown | 60% | 75% | APC, ATM, NF1 | APC |
| 7 | UCOGC+PDAC | Resection | 110 mm | T3N1 | Yes | 5.6 | Unknown | 60% | 80% | KRAS, TP53 | |
| 8 | UCOGC | Resection | 140 mm | T3NXM1 | Yes | 0.1 | No | 40% | 5% |
TP53, KRAS, FBXW7 |
RET |
| 9 | UCOGC | Liver metastasis | >100 mm | T4NXM1 | Yes | 3.6 | Unknown | 20% | 25% | KRAS | SRC |
| 10 | UCOGC | Resection | 35 mm | T2N0M1 | Yes | 171 | Chemotherapy, radiotherapy | 40% | 0% | TP53 | CHEK2, PDGFRA/MTOR/ERBB |
| 11 | UCOGC+IPMN | Resection | 9 mm UCOGC, 60 mm IPMN | T1bN0 | No | 89 | No | 60% | 40% |
KRAS, TP53 CDKN2A |
|
| 12 | UCOGC+IPMN | Resection | 5 mm UCOGC 70 mm IPMN | T1aN0 | No | 49 | Chemotherapy | 20% | 50% | KRAS, ATR | CHEK2, FGFR3 |
| 13 | UCOGC+PDAC | Needle biopsy UCOGC+PDAC | 34 mm | T2N1 | Unknown | Unknown | Unknown | 50% | 5% |
KRAS, TP53, CDKN2A, FGFR4 |
FAT1 |